RT Journal Article
SR Electronic
T1 Penalized regression for left-truncated and right-censored survival data
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.02.09.21251373
DO 10.1101/2021.02.09.21251373
A1 McGough, Sarah F.
A1 Incerti, Devin
A1 Lyalina, Svetlana
A1 Copping, Ryan
A1 Narasimhan, Balasubramanian
A1 Tibshirani, Robert
YR 2021
UL http://medrxiv.org/content/early/2021/02/12/2021.02.09.21251373.abstract
AB High-dimensional data are becoming increasingly common in the medical field as large volumes of patient information are collected and processed by high-throughput screening, electronic health records (EHRs), and comprehensive genomic testing. Statistical models that attempt to study the effects of many predictors on survival typically implement feature selection or penalized methods to mitigate the undesirable consequences of overfitting. In some cases survival data is also left-truncated which can give rise to an immortal time bias, but penalized survival methods that adjust for left truncation are not commonly implemented. To address these challenges, we apply a penalized Cox proportional hazards model for left-truncated and right-censored survival data and assess implications of left truncation adjustment on bias and interpretation. We use simulation studies and a high-dimensional, real-world clinico-genomic database (CGDB) to highlight the pitfalls of failing to account for left truncation in survival modeling.Competing Interest StatementR. Tibshirani and B. Narasimhan are paid consultants for Roche.Funding StatementThis study was funded by Genentech, Inc.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:N/AAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data that support the findings of this study have been originated by Flatiron Health, Inc. and Foundation Medicine, Inc. These de-identified data may be made available upon request, and are subject to a license agreement with Flatiron Health and Foundation Medicine; interested researchers should contact <cgdb-fmi{at}flatiron.com> to determine licensing terms. Code used to produce the analysis is publicly available at https://github.com/phcanalytics/coxnet-ltrc. https://github.com/phcanalytics/coxnet-ltrc